Clinical Features of Patients with Carbapenem Nonsusceptible Klebsiella Pneumoniae and Escherichia Coli in Intensive Care Units: a Nationwide Multicenter Study in Taiwan
Overview
Microbiology
Authors
Affiliations
Background: Patients in intensive care units (ICUs) are especially prone to colonization and infection by carbapenem-resistant Enterobacteriaceae. We conducted a multicenter investigation to study the clinical and microbiological characteristics of patients with carbapenem nonsusceptible Klebsiella pneumoniae and Escherichia coli in ICUs of Taiwanese hospitals.
Methods: Patients with carbapenem nonsusceptible K. pneumoniae and E. coli in ICUs from nine medical centers and eight regional hospitals in Taiwan were enrolled in 2012. Carbapenem nonsusceptibility was defined as a minimum inhibitory concentration of at least 2 mg/L for imipenem or meropenem. Clinical characteristics and risk factors for 30-day mortality were analyzed. Isolates were screened for antibiotic susceptibility and β-lactamase genes.
Results: A total of 66 cases infected (n = 46) or colonized (n = 20) with carbapenem nonsusceptible K. pneumoniae (n = 60) and E. coli (n = 6) were identified during the study period. Nineteen isolates had genes that encoded carbapenemases (28.8%), including Klebsiella pneumoniae carbapenemase-2 (KPC-2) (n = 14), imipenemase-8 (IMP-8) (n = 1), Verona integron-encoded metallo-β-lactamase (VIM) (n = 3), and New Delhi metallo-β-lactamase-1 (NDM-1) (n = 1). The in-hospital mortality associated with non-susceptible K. pneumoniae and E. coli was 50%. The 30-day mortality of the 46 patients with infection was 50%. Septic shock was the only independent risk factor for 30-day mortality in patients with infection. The 30-day mortality rate was similar between patients with combination therapy and monotherapy.
Conclusion: Patients who acquired carbapenem nonsusceptible K. pneumoniae and E. coli in ICUs have a high mortality rate. Further clinical study is needed to deal with this emerging challenge.
Kim M, Jeon K, Kym D, Jung J, Jang Y, Han S Antimicrob Resist Infect Control. 2025; 14(1):3.
PMID: 39881424 PMC: 11780852. DOI: 10.1186/s13756-025-01514-9.
Odoko D, Kumalo A, Alemu G, Demisse T, Mulugeta T, Temesgen M Front Microbiol. 2024; 15:1417425.
PMID: 39588105 PMC: 11586188. DOI: 10.3389/fmicb.2024.1417425.
Aon M, Aoun A, Al Shami A, Alharbi A, Aljenfawi K, Al-Anazi S Cureus. 2024; 16(2):e53606.
PMID: 38449962 PMC: 10915714. DOI: 10.7759/cureus.53606.
Hu Q, Chen J, Sun S, Deng S Infect Drug Resist. 2022; 15:6907-6926.
PMID: 36465807 PMC: 9717588. DOI: 10.2147/IDR.S390635.
Lee C, Chiu C, Lee J, Tsai P, Ko W, Hung Y Infect Drug Resist. 2022; 15:6287-6295.
PMID: 36337933 PMC: 9635385. DOI: 10.2147/IDR.S386309.